Clinical Trial Update: Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating antazoline for rapid cardioversion in paroxysmal atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Atrial Fibrillation

Drugs mentioned

• Antazoline (antazoline)

Snippet

Sponsor: National Institute of Cardiology, Warsaw, Poland | Conditions: Paroxysmal Atrial Fibrillation | Phase 4 | Status: COMPLETED